Biology:P-glycoprotein

From HandWiki
Short description: Mammalian protein found in Homo sapiens


A representation of the 3D structure of the protein myoglobin showing turquoise α-helices.
Generic protein structure example
ABCB1 is differentially expressed in 97 experiments [93 up/106 dn]: 26 organism parts: kidney [2 up/0 dn], bone marrow [0 up/2 dn], ...; 29 disease states: normal [10 up/3 dn], glioblastoma [0 up/2 dn], ...; 30 cell types, 22 cell lines, 11 compound treatments and 16 other conditions.
Factor Value Factor Up/Down
Legend: Atlas-legend.png – number of studies the gene is up/down in
Normal Disease state 10/3
None Compound treatment 3/0
Stromal cell Cell type 1/2
Kidney Cell type 2/0
MDA-MB-231 Cell line 0/2
Glioblastoma Disease state 0/2
Epithelial cell Cell type 0/2
HeLa Cell line 0/2
Primary Disease staging 2/0
Bone marrow Organism part 0/2
ABCB1 expression data in ATLAS

P-glycoprotein 1 (permeability glycoprotein, abbreviated as P-gp or Pgp) also known as multidrug resistance protein 1 (MDR1) or ATP-binding cassette sub-family B member 1 (ABCB1) or cluster of differentiation 243 (CD243) is an important protein of the cell membrane that pumps many foreign substances out of cells. More formally, it is an ATP-dependent efflux pump with broad substrate specificity. It exists in animals, fungi, and bacteria, and it likely evolved as a defense mechanism against harmful substances.

P-gp is extensively distributed and expressed in the intestinal epithelium where it pumps xenobiotics (such as toxins or drugs) back into the intestinal lumen, in liver cells where it pumps them into bile ducts, in the cells of the proximal tubule of the kidney where it pumps them into urinary filtrate (in the proximal tubule), and in the capillary endothelial cells composing the blood–brain barrier and blood–testis barrier, where it pumps them back into the capillaries.

P-gp is a glycoprotein that in humans is encoded by the ABCB1 gene.[1] P-gp is a well-characterized ABC-transporter (which transports a wide variety of substrates across extra- and intracellular membranes) of the MDR/TAP subfamily.[2] The normal excretion of xenobiotics back into the gut lumen by P-gp pharmacokinetically reduces the efficacy of some pharmaceutical drugs (which are said to be P-gp substrates). In addition, some cancer cells also express large amounts of P-gp, further amplifying that effect and rendering these cancers multidrug resistant. Many drugs inhibit P-gp, typically incidentally rather than as their main mechanism of action; some foods do as well.[3] Any such substance can sometimes be called a P-gp inhibitor.

P-gp was discovered in 1971 by Victor Ling.

Gene

A 2015 review of polymorphisms in ABCB1 found that "the effect of ABCB1 variation on P-glycoprotein expression (messenger RNA and protein expression) and/or activity in various tissues (e.g. the liver, gut and heart) appears to be small. Although polymorphisms and haplotypes of ABCB1 have been associated with alterations in drug disposition and drug response, including adverse events with various ABCB1 substrates in different ethnic populations, the results have been majorly conflicting, with limited clinical relevance."[4]

Protein

P-gp is a 170 kDa transmembrane glycoprotein, which includes 10-15 kDa of N-terminal glycosylation. The N-terminal half of the molecule contains 6 transmembrane domains, followed by a large cytoplasmic domain with an ATP-binding site, and then a second section with 6 transmembrane domains and an ATP-binding site that shows over 65% of amino acid similarity with the first half of the polypeptide.[5] In 2009, the first structure of a mammalian P-glycoprotein was solved (3G5U).[6] The structure was derived from the mouse MDR3 gene product heterologously expressed in Pichia pastoris yeast. The structure of mouse P-gp is similar to structures of the bacterial ABC transporter MsbA (3B5W and 3B5X)[7] that adopt an inward facing conformation that is believed to be important for binding substrate along the inner leaflet of the membrane. Additional structures (3G60 and 3G61) of P-gp were also solved revealing the binding site(s) of two different cyclic peptide substrate/inhibitors. The promiscuous binding pocket of P-gp is lined with aromatic amino acid side chains.

Through Molecular Dynamic (MD) simulations, this sequence was proved to have a direct impact in the transporter's structural stability (in the nucleotide-binding domains) and defining a lower boundary for the internal drug-binding pocket.[8]

Species, tissue, and subcellular distribution

P-gp is expressed primarily in certain cell types in the liver, pancreas, kidney, colon, and jejunum.[9] P-gp is also found in brain capillary endothelial cells.[10]

Function

Substrate enters P-gp either from an opening within the inner leaflet of the membrane or from an opening at the cytoplasmic side of the protein. ATP binds at the cytoplasmic side of the protein. Following binding of each, ATP hydrolysis shifts the substrate into a position to be excreted from the cell. Release of the phosphate (from the original ATP molecule) occurs concurrently with substrate excretion. ADP is released, and a new molecule of ATP binds to the secondary ATP-binding site. Hydrolysis and release of ADP and a phosphate molecule resets the protein, so that the process can start again.

The protein belongs to the superfamily of ATP-binding cassette (ABC) transporters. ABC proteins transport various molecules across extra- and intra-cellular membranes. ABC genes are divided into seven distinct subfamilies (ABC1, MDR/TAP, MRP, ALD, OABP, GCN20, White). This protein is a member of the MDR/TAP subfamily. Members of the MDR/TAP subfamily are involved in multidrug resistance. P-gp is an ATP-dependent drug efflux pump for xenobiotic compounds with broad substrate specificity. It is responsible for decreased drug accumulation in multidrug-resistant cells and often mediates the development of resistance to anticancer drugs. This protein also functions as a transporter in the blood–brain barrier. Mutations in this gene are associated with colchicine resistance and Inflammatory bowel disease 13. Alternative splicing and the use of alternative promoters results in multiple transcript variants. [11]

P-gp transports various substrates across the cell membrane including:

Its ability to transport the above substrates accounts for the many roles of P-gp including:

  • Regulating the distribution and bioavailability of drugs
    • Increased intestinal expression of P-glycoprotein can reduce the absorption of drugs that are substrates for P-glycoprotein. Thus, there is a reduced bioavailability, and therapeutic plasma concentrations are not attained. On the other hand, supratherapeutic plasma concentrations and drug toxicity may result because of decreased P-glycoprotein expression
    • Active cellular transport of antineoplastics resulting in multidrug resistance to these drugs
  • The removal of toxic metabolites and xenobiotics from cells into urine, bile, and the intestinal lumen
  • The transport of compounds out of the brain across the blood–brain barrier
  • Digoxin uptake
  • Prevention of ivermectin and loperamide entry into the central nervous system
  • The migration of dendritic cells
  • Protection of hematopoietic stem cells from toxins.[2]

It is inhibited by many drugs, such as amiodarone, azithromycin, captopril, clarithromycin, cyclosporine, piperine, quercetin, quinidine, quinine, reserpine, ritonavir, tariquidar, and verapamil.[13]

Regulation of expression and function of P-gp in cancer cells

At the transcriptional level, the expression of P-gp has been intensively studied, and numerous transcription factors and pathways are known to play roles. A variety of transcription factors, such as p53,[14] YB-1,[15] and NF-κB[16] are involved in the direct regulation of P-gp by binding to the promoter regions of the P-gp gene. Many cell signaling pathways are also involved in transcriptional regulation of P-gp. For example, the PI3K/Akt pathway[15] and the Wnt/β-catenin pathway[17] were reported to positively regulate the expression of P-gp. Mitogen-activated protein kinase (MAPK) signaling includes three pathways: the classical MAPK/ERK pathway, the p38 MAPK pathway, and the c-Jun N-terminal kinase (JNK) pathway, all of which were reported to have implications in the regulation of the expression of P-gp. Studies suggested that the MAPK/ERK pathway is involved in the positive regulation of P-gp;[18] the p38 MAPK pathway negatively regulates the expression of the P-gp gene;[19] and the JNK pathway was reported to be involved in both positive regulation and negative regulation of P-gp.[20][21]

After 2008, microRNAs (miRNAs) were identified as new players in regulating the expression of P-gp in both transcriptional and post-transcriptional levels. Some miRNAs decrease the expression of P-gp. For example, miR-200c down-regulates the expression of P-gp through the JNK signaling pathway[20] or ZEB1 and ZEB2;[22] miR-145 down-regulates the mRNA of P-gp by directly binding to the 3'-UTR of the gene of P-gp and thus suppresses the translation of P-gp.[23] Some other miRNAs increase the expression of P-gp. For example, miR-27a up-regulates P-gp expression by suppressing the Raf kinase inhibitor protein (RKIP);[24] alternatively, miR-27a can also directly bind to the promoter of the P-gp gene, which works in a similar way with the mechanism of action of transcriptional factors.[25]

The expression of P-gp is also regulated by post-translational events, such as post-transcriptional modification, degradation, and intracellular trafficking of P-gp. Pim-1 protects P-gp from ubiquitination and the following degradation in the proteasome.[26] Small GTPases Rab5 down-regulates the endocytotic trafficking of P-gp and thus increases the functional P-gp level on the cell membrane;[27] while Small GTPases Rab4 work in an opposite way: Rab4 down-regulates the exocytotic trafficking of P-gp from intracellular compartments to the cell membrane, and therefore decreases the functional P-gp level on the cell membrane.[28]

Clinical significance

Drug interactions

Some common pharmacological inhibitors of P-glycoprotein include: amiodarone, clarithromycin, ciclosporin, colchicine, diltiazem, erythromycin, felodipine, ketoconazole,[29] lansoprazole, omeprazole and other proton-pump inhibitors, nifedipine, paroxetine, reserpine,[30] saquinavir,[29] sertraline, quinidine, tamoxifen, verapamil,[31] and duloxetine.[32] Elacridar and CP 100356 are other common[citation needed] P-gp inhibitors. Zosuquidar and tariquidar were also developed with this in mind.[clarification needed] Lastly, valspodar and reversan are other examples of such agents. ABCB1 is linked to the daily dose of warfarin required to maintain the INR to a target of 2.5. Patients with the GT or TT genotypes of the 2677G>T SNP require around 20% more warfarin daily.[33]

Common pharmacological inducers of P-glycoprotein include carbamazepine, dexamethasone, doxorubicin, nefazodone, phenobarbital, phenytoin, prazosin, rifampicin, St. John's wort, tenofovir, tipranavir, trazodone, and vinblastine.[34]

Substrates of P-glycoprotein are susceptible to changes in pharmacokinetics due to drug interactions with P-gp inhibitors or inducers. Some of these substrates include colchicine, ciclosporin, dabigatran,[30] digoxin, diltiazem,[35] fexofenadine, indinavir, morphine, and sirolimus.[29]

Diseases (non-cancer)

Decreased P-gp expression has been found in Alzheimer's disease brains.[36]

Altered P-gp function has also been linked to inflammatory bowel diseases (IBD);[37] however, due to its ambivalent effects in intestinal inflammation many questions remain so far unanswered.[38] While decreased efflux activity may promote disease susceptibility and drug toxicity, increased efflux activity may confer resistance to therapeutic drugs in IBD.[38] Mice deficient in MDR1A develop chronic intestinal inflammation spontaneously, which appears to resemble human ulcerative colitis.[39]

Cancer

P-gp efflux activity is capable of lowering intracellular concentrations of otherwise beneficial compounds, such as chemotherapeutics and other medications, to sub-therapeutic levels. Consequently, P-gp overexpression is one of the main mechanisms behind decreased intracellular drug accumulation and development of multidrug resistance in human multidrug-resistant (MDR) cancers.[40][41]

History

P-gp was first characterized in 1976. P-gp was shown to be responsible for conferring multidrug resistance upon mutant cultured cancer cells that had developed resistance to cytotoxic drugs.[2][42]

The structure of mouse P-gp, which has 87% sequence identity to human P-gp, was resolved by x-ray crystallography in 2009.[6] The first structure of human P-gp was solved in 2018, with the protein in its ATP-bound, outward-facing conformation. [43]

Research

Radioactive verapamil can be used for measuring P-gp function with positron emission tomography.[44]

P-gp is also used to differentiate transitional B cells from naive B cells. Dyes such as rhodamine 123 and MitoTracker dyes from Invitrogen can be used to make this differentiation.[45]

MDR1 as a drug target

It has been suggested that MDR1 inhibitors might treat various diseases, especially cancers, but none have done well in clinical trials.[46]

Single nucleotide polymorphism rs1045642

Single Nucleotide Polymorphism are important for the differential activity of the PGP pump.

Homozygous subjects, identified with the TT genotype, are usually more able to extrude xenobiotics from the cell. A Homozygous genotype for the allele ABCB1/MDR1 is capable of a higher absorption from the blood vessels and a lower extrusion into the lumen. Xenobiotics are extruded at a lower rate with heterozygous (CT) alleles compared to homozygous ones. [47]

References

  1. ↑ "The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation". The Journal of Biological Chemistry 262 (2): 505–8. January 1987. doi:10.1016/S0021-9258(19)75806-2. PMID 3027054. 
  2. ↑ 2.0 2.1 2.2 Dean, Michael (2002-11-01). "The Human ATP-Binding Cassette (ABC) Transporter Superfamily". National Library of Medicine (US), NCBI. https://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=mono_001.chapter.137. 
  3. ↑ "Intestinal Drug Interactions Mediated by OATPs: A Systematic Review of Preclinical and Clinical Findings". Journal of Pharmaceutical Sciences 106 (9): 2312–2325. September 2017. doi:10.1016/j.xphs.2017.04.004. PMID 28414144. 
  4. ↑ "Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature". Clinical Pharmacokinetics 54 (7): 709–35. July 2015. doi:10.1007/s40262-015-0267-1. PMID 25860377. 
  5. ↑ Franck Viguié (1998-03-01). "ABCB1". Atlas of Genetics and Cytogenetics in Oncology and Haematology. http://atlasgeneticsoncology.org//Genes/PGY1ID105.html. 
  6. ↑ 6.0 6.1 "Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding". Science 323 (5922): 1718–22. March 2009. doi:10.1126/science.1168750. PMID 19325113. Bibcode: 2009Sci...323.1718A. 
  7. ↑ "Flexibility in the ABC transporter MsbA: Alternating access with a twist". Proceedings of the National Academy of Sciences of the United States of America 104 (48): 19005–10. November 2007. doi:10.1073/pnas.0709388104. PMID 18024585. Bibcode: 2007PNAS..10419005W. 
  8. ↑ "Insights on P-Glycoprotein's Efflux Mechanism Obtained by Molecular Dynamics Simulations". Journal of Chemical Theory and Computation 8 (6): 1853–64. June 2012. doi:10.1021/ct300083m. PMID 26593820. 
  9. ↑ "Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues". Proceedings of the National Academy of Sciences of the United States of America 84 (21): 7735–8. November 1987. doi:10.1073/pnas.84.21.7735. PMID 2444983. Bibcode: 1987PNAS...84.7735T. 
  10. ↑ "P-Glycoprotein, a gatekeeper in the blood-brain barrier". Advanced Drug Delivery Reviews 36 (2–3): 179–194. April 1999. doi:10.1016/S0169-409X(98)00085-4. PMID 10837715. 
  11. ↑ "Entrez Gene: ABCB1". https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=5243. 
  12. ↑ "Desloratadine: Drug information". https://www.uptodate.com/contents/desloratadine-drug-information. 
  13. ↑ "Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers". FDA. 26 May 2021. https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm. 
  14. ↑ "Wild type p53 stimulates expression from the human multidrug resistance promoter in a p53-negative cell line". The Journal of Biological Chemistry 270 (4): 1894–8. January 1995. doi:10.1074/jbc.270.4.1894. PMID 7829527. 
  15. ↑ 15.0 15.1 "Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression". Nature Medicine 3 (4): 447–50. April 1997. doi:10.1038/nm0497-447. PMID 9095180. 
  16. ↑ "NF-kappaB-mediated induction of mdr1b expression by insulin in rat hepatoma cells". The Journal of Biological Chemistry 272 (24): 15174–83. June 1997. doi:10.1074/jbc.272.24.15174. PMID 9182539. 
  17. ↑ "Activation of beta-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells". Journal of Neurochemistry 106 (4): 1855–65. August 2008. doi:10.1111/j.1471-4159.2008.05537.x. PMID 18624906. 
  18. ↑ "Activation of phospholipase C induces the expression of the multidrug resistance (MDR1) gene through the Raf-MAPK pathway". Molecular Pharmacology 60 (4): 674–80. October 2001. PMID 11562428. 
  19. ↑ "TFPI-2 downregulates multidrug resistance protein in 5-FU-resistant human hepatocellular carcinoma BEL-7402/5-FU cells". Anatomical Record 296 (1): 56–63. January 2013. doi:10.1002/ar.22611. PMID 23125179. 
  20. ↑ 20.0 20.1 "miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer". Molecular Cancer Therapeutics 13 (12): 3137–51. December 2014. doi:10.1158/1535-7163.MCT-14-0167. PMID 25205654. 
  21. ↑ "PSC833, cyclosporine analogue, downregulates MDR1 expression by activating JNK/c-Jun/AP-1 and suppressing NF-kappaB". Cancer Chemotherapy and Pharmacology 65 (6): 1131–6. May 2010. doi:10.1007/s00280-009-1121-7. PMID 19763573. 
  22. ↑ "The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2". Genes & Development 22 (7): 894–907. April 2008. doi:10.1101/gad.1640608. PMID 18381893. 
  23. ↑ "Negative regulation of miR-145 by C/EBP-β through the Akt pathway in cancer cells". Nucleic Acids Research 40 (14): 6683–92. August 2012. doi:10.1093/nar/gks324. PMID 22495929. 
  24. ↑ "miR-27a regulates cisplatin resistance and metastasis by targeting RKIP in human lung adenocarcinoma cells". Molecular Cancer 13: 193. August 2014. doi:10.1186/1476-4598-13-193. PMID 25128483. 
  25. ↑ "Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma". Digestive Diseases and Sciences 55 (9): 2545–51. September 2010. doi:10.1007/s10620-009-1051-6. PMID 19960259. 
  26. ↑ "Pim-1 kinase protects P-glycoprotein from degradation and enables its glycosylation and cell surface expression". Molecular Pharmacology 78 (2): 310–8. August 2010. doi:10.1124/mol.109.061713. PMID 20460432. 
  27. ↑ "The small GTPases Rab5 and RalA regulate intracellular traffic of P-glycoprotein". Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1773 (7): 1062–72. July 2007. doi:10.1016/j.bbamcr.2007.03.023. PMID 17524504. 
  28. ↑ "Rab4 interacts with the human P-glycoprotein and modulates its surface expression in multidrug resistant K562 cells". International Journal of Cancer 128 (1): 192–205. January 2011. doi:10.1002/ijc.25310. PMID 20209493. 
  29. ↑ 29.0 29.1 29.2 John r. Horn, Pharmd; Philip Hansten, Pharmd (December 2008). "Drug Transporters: The Final Frontier for Drug Interactions". Pharmacy Times. https://www.pharmacytimes.com/publications/issue/2008/2008-12/2008-12-8474. Retrieved 2018-11-30. 
  30. ↑ 30.0 30.1 Research, Center for Drug Evaluation and. "Drug Interactions & Labeling – Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers" (in en). https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table5-2. 
  31. ↑ Srivalli, KMR; Lakshmi, PK (July 2012). "Overview of P-glycoprotein inhibitors: a rational outlook". Brazilian Journal of Pharmaceutical Sciences 48 (3): 353–367. doi:10.1590/S1984-82502012000300002. open access
  32. ↑ "In vitro and in vivo evaluation of the effects of duloxetine on P-gp function". Human Psychopharmacology 25 (7–8): 553–9. November 2010. doi:10.1002/hup.1152. PMID 21312289. 
  33. ↑ Gopisankar MG, Hemachandren M, Surendiran A. ABCB1 266G-T single nucleotide polymorphism influences warfarin dose requirement for warfarin maintenance therapy. Br J Biomed Sci 2019:76;150-152
  34. ↑ Health, Ministry of (2015). "Use of Non-Vitamin K Antagonist Oral Anticoagulants (NOAC) in Non-Valvular Atrial Fibrillation – Province of British Columbia. Appendix A (2015)." (in en). https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/bc-guidelines/noac. 
  35. ↑ "Diltiazem: Drug information". https://www.uptodate.com/contents/diltiazem-drug-information. 
  36. ↑ "Blood-Brain Barrier ABC-transporter P-glycoprotein in Alzheimer's Disease: Still a Suspect?". Current Pharmaceutical Design 22 (38): 5808–5816. 2016. doi:10.2174/1381612822666160804094544. PMID 27494062. 
  37. ↑ "Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease?". Gut 52 (5): 759–66. May 2003. doi:10.1136/gut.52.5.759. PMID 12692067. 
  38. ↑ 38.0 38.1 "P-glycoprotein multidrug transporter in inflammatory bowel diseases: More questions than answers". World Journal of Gastroenterology 23 (9): 1513–1520. March 2017. doi:10.3748/wjg.v23.i9.1513. PMID 28321153. 
  39. ↑ "The mdr1a-/- mouse model of spontaneous colitis: a relevant and appropriate animal model to study inflammatory bowel disease". Immunologic Research 31 (2): 151–9. 2005. doi:10.1385/ir:31:2:151. PMID 15778512. 
  40. ↑ "Signal transduction pathways and transcriptional mechanisms of ABCB1/Pgp-mediated multiple drug resistance in human cancer cells". The Journal of International Medical Research 40 (2): 426–35. April 2012. doi:10.1177/147323001204000204. PMID 22613403. 
  41. ↑ "New insight into p-glycoprotein as a drug target". Anti-Cancer Agents in Medicinal Chemistry 13 (1): 159–70. January 2013. doi:10.2174/1871520611307010159. PMID 22931413. 
  42. ↑ "A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants". Biochimica et Biophysica Acta (BBA) - Biomembranes 455 (1): 152–62. November 1976. doi:10.1016/0005-2736(76)90160-7. PMID 990323. 
  43. ↑ "Molecular structure of human P-glycoprotein in the ATP-bound, outward-facing conformation". Science 359 (6378): 915–919. February 2018. doi:10.1126/science.aar7389. PMID 29371429. Bibcode: 2018Sci...359..915K. 
  44. ↑ "Fully automated high yield synthesis of (R)- and (S)-[C-11]verapamil for measuring P-glycoprotein function with positron emission tomography". Journal of Labelled Compounds and Radiopharmaceuticals 45 (14): 1199–1207. 2002. doi:10.1002/jlcr.632. 
  45. ↑ "ABCB1 transporter discriminates human resting naive B cells from cycling transitional and memory B cells". European Journal of Immunology 35 (12): 3433–41. December 2005. doi:10.1002/eji.200535364. PMID 16259010. 
  46. ↑ Inhibiting Cancer Drug Resistance Gene May Not Be Best Approach Apr 2020
  47. ↑ "AABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence". Hum Mol Genet 17 (14): 2219–2227. 2008. doi:10.1093/hmg/ddn122. PMID 18424454. 

Further reading

External links

This article incorporates text from the United States National Library of Medicine, which is in the public domain.



Retrieved from "https://handwiki.org/wiki/index.php?title=Biology:P-glycoprotein&oldid=3629209"